Gilead Sciences Dividende

Zukünftiges Wachstum Kriterienprüfungen 4/6

Gilead Sciences ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 3.43%.

Wichtige Informationen

3.4%

Dividendenausschüttung

0.6%

Rückkaufsrendite

Gesamte Aktionärsrendite	4.0%
Zukünftige Dividendenrendite	3.7%
Wachstum der Dividende	6.9%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	US$3.080
Ausschüttungsquote	360%

Aktuelle Dividendenentwicklung

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Mar 13

Recent updates

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Apr 22

Gilead Sciences: Some Signs Of An Impending Bottom

Apr 22

Gilead Sciences: Realizing Financial Projections Is Key

Mar 20

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Mar 13

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: GILDDie Dividende je Aktie war in den letzten 10 Jahren stabil.

Wachsende Dividende: GILDDie Dividendenzahlungen des Unternehmens sind in den letzten 10 Jahren gestiegen.

Dividendenrendite im Vergleich zum Markt

Gilead Sciences Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von GILD im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (GILD)	3.4%
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.5%
Branchendurchschnitt (Biotechs)	2.2%
Analystenprognose (GILD) (bis zu 3 Jahre)	3.7%

Bemerkenswerte Dividende: GILDDie Dividende des Unternehmens (3.43%) ist höher als die der untersten 25% der Dividendenzahler auf dem US Markt (1.44%).

Hohe Dividende: GILDDie Dividende des Unternehmens (3.43%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt US (4.51%) niedrig.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Mit seiner hohen Ausschüttungsquote (359.7%) sind die Dividendenzahlungen von GILD nicht ausreichend durch die Erträge gedeckt.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Mit einer angemessenen Ausschüttungsquote (55.6%) sind die Dividendenzahlungen von GILD durch den Cashflow gedeckt.

Gilead Sciences Dividende

Zukünftiges Wachstum Kriterienprüfungen 4/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Upcoming dividend of US$0.77 per share

Upcoming dividend of US$0.77 per share

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Upcoming dividend of US$0.77 per share

Recent updates

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Chief Medical Officer notifies of intention to sell stock

Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It

Chief Commercial Officer notifies of intention to sell stock

Upcoming dividend of US$0.77 per share

Gilead Sciences: Buy This Bargain Before It's Gone

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Consensus EPS estimates fall by 21%

Second quarter dividend of US$0.77 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?

A Look At Gilead Sciences After Its Recent Weakness

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Records Positive Phase III Results In HIV

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen